NBTX

Nanobiotix S.A.

Healthcare
Biotechnology
$1.20B market cap

Forecast run · Oct 15, 2026Upside rank 446 of 3,171

Model Signal

ForecastQ Daily Probabilities

53.3%

21.8%

61.0%

Analyst Consensus

Recommendation2.25/5 Buy

Last price$23.68

Price target$38.00

Implied move+60.5%

Analysts4

ForecastQ Portfolios

NBTX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.